Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRP | O00591 | 3/20 | 0.42 |
| ▸ | GABRD | O14764 | 3/20 | 0.42 |
| ▸ | GABRA1 | P14867 | 3/20 | 0.42 |
| ▸ | GABRB1 | P18505 | 3/20 | 0.42 |
| ▸ | GABRG2 | P18507 | 3/20 | 0.42 |
| ▸ | GABRB3 | P28472 | 3/20 | 0.42 |
| ▸ | GABRA5 | P31644 | 3/20 | 0.42 |
| ▸ | GABRA3 | P34903 | 3/20 | 0.42 |
| ▸ | GABRA2 | P47869 | 3/20 | 0.42 |
| ▸ | GABRB2 | P47870 | 3/20 | 0.42 |
| ▸ | GABRA4 | P48169 | 3/20 | 0.42 |
| ▸ | GABRE | P78334 | 3/20 | 0.42 |
| ▸ | GABRA6 | Q16445 | 3/20 | 0.42 |
| ▸ | GABRG1 | Q8N1C3 | 3/20 | 0.42 |
| ▸ | GABRG3 | Q99928 | 3/20 | 0.42 |
| ▸ | GABRQ | Q9UN88 | 3/20 | 0.42 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | ENPEP | Q07075 | 3/20 | 0.37 |
| ▸ | LMNA | P02545 | 3/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Valiloxybate SCHEMBL27165970 | 1.00 | GABRP (0.42) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| Valiloxybate SCHEMBL3730354 | 1.00 | GABRP (0.42) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| Valiloxybate SCHEMBL3730350 | 1.00 | GABRP (0.42) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| Valiloxybate SCHEMBL34468016 | 0.98 | GABRP (0.41) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| Valiloxybate SCHEMBL34467996 | 0.96 | GABRP (0.39) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL7603837 | 0.94 | ALDH1A1 (0.47) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL7603840 | 0.94 | ALDH1A1 (0.47) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL27138529 | 0.94 | ALDH1A1 (0.47) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| Valiloxybate SCHEMBL34467970 | 0.92 | GABRP (0.36) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| Valiloxybate SCHEMBL34468040 | 0.90 | GABRP (0.35) | GABRPGABRDGABRA1GABRB1GABRG2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 60 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4167971-A1 | CONTROLLED RELEASE GRANULATIONS OF WATER-SOLUBLE ACTIVE PHARMACEUTICAL INGREDIENTS | XWPharma Ltd. (KY) | 2023-04-26 | — | — | EP | claimed |
| EP-4167966-A1 | PHARMACEUTICAL GRANULATIONS OF WATER-SOLUBLE ACTIVE PHARMACEUTICAL INGREDIENTS | XWPharma Ltd. (KY) | 2023-04-26 | — | — | EP | claimed |
| CN-115803017-A | Pharmaceutical granulation of water-soluble active pharmaceutical ingredients | 凯瑞康宁生物工程有限公司 | 2023-03-14 | — | — | CN | claimed |
| CN-115038432-A | Controlled release granulation of water soluble active pharmaceutical ingredients | 凯瑞康宁生物工程（武汉）有限公司 | 2022-09-09 | — | — | CN | claimed |
| US-20220183977-A1 | CONTROLLED RELEASE GRANULATIONS OF WATER-SOLUBLE ACTIVE PHARMACEUTICAL INGREDIENTS | XWPharma Ltd. (KY) | 2022-06-16 | — | — | US | claimed |
| US-11304906-B2 | Controlled release granulations of water-soluble active pharmaceutical ingredients | XWPharma Ltd. (KY) | 2022-04-19 | — | — | US | claimed |
| US-20210393537-A1 | PHARMACEUTICAL GRANULATIONS OF WATER-SOLUBLE ACTIVE PHARMACEUTICAL INGREDIENTS | XWPharma Ltd. (KY) | 2021-12-23 | — | — | US | claimed |
| US-20210393529-A1 | CONTROLLED RELEASE GRANULATIONS OF WATER-SOLUBLE ACTIVE PHARMACEUTICAL INGREDIENTS | XWPharma Ltd. (KY) | 2021-12-23 | — | — | US | claimed |
| WO-2021257832-A1 | PHARMACEUTICAL GRANULATIONS OF WATER-SOLUBLE ACTIVE PHARMACEUTICAL INGREDIENTS | XWPharma Ltd. (KY) | 2021-12-23 | — | — | WO | claimed |
| WO-2021257886-A1 | CONTROLLED RELEASE GRANULATIONS OF WATER-SOLUBLE ACTIVE PHARMACEUTICAL INGREDIENTS | XWPharma Ltd. (KY) | 2021-12-23 | — | — | WO | claimed |
| US-10774031-B2 | Prodrugs of gamma-hydroxybutyric acid, compositions and uses thereof | XW LABORATORIES INC. (KY) | 2020-09-15 | — | — | US | claimed |
| US-20200223783-A1 | PRODRUGS OF GAMMA-HYDROXYBUTYRIC ACID, COMPOSITIONS AND USES THEREOF | XW LABORATORIES INC. (KY) | 2020-07-16 | — | — | US | claimed |
| US-20250262157-A1 | CONTROLLED RELEASE GRANULATIONS OF WATER-SOLUBLE ACTIVE PHARMACEUTICAL INGREDIENTS | XWPharma Ltd. (KY) | 2025-08-21 | — | — | US | disclosed |
| US-12337066-B2 | Controlled release granulations of water-soluble active pharmaceutical ingredients | XWPharma Ltd. (KY) | 2025-06-24 | — | — | US | disclosed |
| CN-117618393-A | Controlled release granulation of water-soluble active pharmaceutical ingredient | 凯瑞康宁生物工程（武汉）有限公司 | 2024-03-01 | — | — | CN | disclosed |
| CN-115038432-B | Controlled release granulation of water-soluble active pharmaceutical ingredient | 凯瑞康宁生物工程（武汉）有限公司 | 2023-12-26 | — | — | CN | disclosed |
| WO-2017050259-A1 | PRODRUGS OF GAMMA-HYDROXYBUTYRIC ACID, COMPOSITIONS AND USES THEREOF | XW LABORATORIES INC. (KY) | 2017-03-30 | — | — | WO | disclosed |
| WO-2017050259-A1 | PRODRUGS OF GAMMA-HYDROXYBUTYRIC ACID, COMPOSITIONS AND USES THEREOF | XW LABORATORIES INC. (KY) | 2017-03-30 | — | — | WO | disclosed |
| EP-0988304-A1 | NUCLEOSIDES ANALOGUES, SUCH AS ANTIVIRALS INCLUDING INHIBITORS OF RETROVIRAL REVERSE TRANSCRIPTASE AND THE DNA POLYMERASE OF HEPATITIS B VIRUS (HBV) | MEDIVIR AB (SE) | 2000-03-29 | — | — | EP | disclosed |
| WO-1999009031-A1 | NUCLEOSIDES ANALOGUES, SUCH AS ANTIVIRALS INCLUDING INHIBITORS OF RETROVIRAL REVERSE TRANSCRIPTASE AND THE DNA POLYMERASE OF HEPATITIS B VIRUS (HBV) | MEDIVIR AB (SE) | 1999-02-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12337066-B2 | Controlled release granulations of water-soluble active pharmaceutical ingredients | GMPS, SI, UGGT1 | GABRP 1338/4885GABRD 844/4885GABRA1 1823/4885 |
| US-20210393529-A1 | CONTROLLED RELEASE GRANULATIONS OF WATER-SOLUBLE ACTIVE PHARMACEUTICAL INGREDIENTS | GMPS, SI, UGGT1 | GABRP 1338/4885GABRD 844/4885GABRA1 1823/4885 |
| US-20250262157-A1 | CONTROLLED RELEASE GRANULATIONS OF WATER-SOLUBLE ACTIVE PHARMACEUTICAL INGREDIENTS | GMPS, SI, UGGT1 | GABRP 1338/4885GABRD 844/4885GABRA1 1823/4885 |
| US-10774031-B2 | Prodrugs of gamma-hydroxybutyric acid, compositions and uses thereof | GABRB3, GABRB2, GABRB1 | GABRP 9/4885GABRD 22/4885GABRA1 26/4885 |
| US-20210393537-A1 | PHARMACEUTICAL GRANULATIONS OF WATER-SOLUBLE ACTIVE PHARMACEUTICAL INGREDIENTS | GMPS, GYS2, SLC18A1 | GABRP 504/4885GABRD 549/4885GABRA1 1140/4885 |
| US-20220183977-A1 | CONTROLLED RELEASE GRANULATIONS OF WATER-SOLUBLE ACTIVE PHARMACEUTICAL INGREDIENTS | GMPS, SI, UGGT1 | GABRP 1338/4885GABRD 844/4885GABRA1 1823/4885 |
| US-11304906-B2 | Controlled release granulations of water-soluble active pharmaceutical ingredients | GMPS, SI, UGGT1 | GABRP 1338/4885GABRD 844/4885GABRA1 1823/4885 |
| US-20200223783-A1 | PRODRUGS OF GAMMA-HYDROXYBUTYRIC ACID, COMPOSITIONS AND USES THEREOF | GABRB3, GABRB2, GABRB1 | GABRP 9/4885GABRD 22/4885GABRA1 26/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.